VTWG logo

VTWGVanguard Russell 2000 Growth ETF

$279.28
$2.97
(1.07%)
Today
Updated: 01:25 PM EDT
Vol13,062.00
52W High$280.77
52W Low$198.84
News
all
press releases
This Critical Materials Stock Surged Over 150% In A Year – The Firm’s Now Ready To Hit 2026 Production Guidance In Just 6 Months
Energy Fuels expects to produce 1.6 million pounds of finished uranium from January through June 2026 at its 100%-owned White Mesa Mill in Utah.
Stocktwits
News Placeholder
More News
News Placeholder
APPS Stock Soars 53%, On Track For Best Single-Day Gains In 11 Months — Why Did BofA Turn Bullish On Digital Turbine?
Digital Turbine reported earnings per share of $0.16 in Q4 on revenue of $143 million, while Wall Street expected an EPS of $0.09 on revenue of $133 million.
Stocktwits
News Placeholder
Should Vanguard Russell 2000 Growth Index Fund ETF Shares (VTWG) Be on Your Investing Radar?
Style Box ETF report for VTWG
Zacks
News Placeholder
WYFI Stock Tumbles Nearly 10% After Q4 Earnings Miss — What's Wall Street's Take?
Craig-Hallum lowered its price target on the company to $21 from $25, while maintaining a ‘Buy’ rating on the stock, according to Investing.com.
Stocktwits
News Placeholder
ATOM Stock Is Falling Today After Atomera Announces Stock Offering At A Deep Discount
The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.
Stocktwits
News Placeholder
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?
Style Box ETF report for VTWG
Zacks
News Placeholder
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism?
The company said that EVO301 achieved highly statistically significant outcomes in adult patients with moderate-to-severe atopic dermatitis.
Stocktwits
News Placeholder
Why Is TeraWulf Stock Rallying More Than 10% After Hours?
With the addition of these sites, TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites.
Stocktwits
News Placeholder
Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs
The company said that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab.
Stocktwits
News Placeholder
TWST Shares Rise 8% — What’s Driving The Rally?
Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.